Abstract
Multi-drug resistance (MDR) is a significant barrier to effective chemotherapy of cancer. The induction of drug metabolizing enzymes (DMEs) and efflux transporters has been regarded as one of the major mechanisms of drug resistance. As a master transcription factor of DMEs and efflux transporters, pregnane X receptor (PXR), an orphan nuclear receptor known for its activation by structurally diverse compounds, is expressed in some cancer cells and tissues, and is implicated as a novel master regulator of MDR in cancers. This review describes recent publications and patents on the mechanism of PXR transcription, the expression of PXR in cancers, and its potential roles in cancer MDR. We also discuss the recent patents published to overcome PXR-mediated MDR and other potential roles of PXR in cancers.
Keywords: Multi-drug resistance, pregnane X receptor, Drug metabolism enzyme, Drug transporter, Cancer treatment, Nuclear receptor, Steroid X receptor, Inhibitor, Chemotherapeutics, Carcinogenesis, Cancer repressor
Recent Patents on Anti-Cancer Drug Discovery
Title: Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Volume: 4 Issue: 1
Author(s): Yakun Chen and Daotai Nie
Affiliation:
Keywords: Multi-drug resistance, pregnane X receptor, Drug metabolism enzyme, Drug transporter, Cancer treatment, Nuclear receptor, Steroid X receptor, Inhibitor, Chemotherapeutics, Carcinogenesis, Cancer repressor
Abstract: Multi-drug resistance (MDR) is a significant barrier to effective chemotherapy of cancer. The induction of drug metabolizing enzymes (DMEs) and efflux transporters has been regarded as one of the major mechanisms of drug resistance. As a master transcription factor of DMEs and efflux transporters, pregnane X receptor (PXR), an orphan nuclear receptor known for its activation by structurally diverse compounds, is expressed in some cancer cells and tissues, and is implicated as a novel master regulator of MDR in cancers. This review describes recent publications and patents on the mechanism of PXR transcription, the expression of PXR in cancers, and its potential roles in cancer MDR. We also discuss the recent patents published to overcome PXR-mediated MDR and other potential roles of PXR in cancers.
Export Options
About this article
Cite this article as:
Chen Yakun and Nie Daotai, Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (1) . https://dx.doi.org/10.2174/157489209787002498
DOI https://dx.doi.org/10.2174/157489209787002498 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunological Aspects of Metritis in Dairy Cows: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Recent Clinical Aspects of Hyperprolactinemia Induced by Antipsychotics
Reviews on Recent Clinical Trials Shedding Light on Serum Vitamin D Concentrations and the Risk of Rarer Cancers
Anti-Cancer Agents in Medicinal Chemistry Quantitative Proteomics for Cancer Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Perspectives of New Therapies for Endometriosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design Natural Products and Cancer Stem Cells
Current Pharmaceutical Design Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Current Medicinal Chemistry Cytokines, Inflammation and Colon Cancer
Current Cancer Drug Targets The Immunohistochemical Assessment of HPV Related Adenocarcinoma: Pathologic and Clinical Prognostic Significance
Current Pharmaceutical Design MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Anticancer Activity of Selenium Nanoparticles <i>In Vitro</i> Studies
Anti-Cancer Agents in Medicinal Chemistry Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Pharmaceutical Design Polo-Like Kinases (Plks) are Prognostic Markers for Gynecologic Malignancies
Current Women`s Health Reviews Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry